Smoking Cessation: Which Options are Best?

The field of smoking cessation has been abuzz since the FDA approved Chantix (varenicline) in 2006. Pfizer’s studies showed better efficacy for Chantix than bupropion (Wellbutrin/Zyban), and the mechanism of action is fascinating. But several controversial issues have arisen to muddy the waters. Reports of psychiatric side effects surfaced, prompting the FDA to issue a public health advisory. And on an unrelated note, a new “cold turkey” quit smoking movement has arisen, filled with critics of pharmacological cures. Let’s look at some of these issues in more detail.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.